ANAB vs IGIC Comparison

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

International General Insurance Holdings Ltd is an international specialty insurance and reinsurance group. It underwrites a diversified portfolio of specialty risks including energy, property, construction and engineering, ports and terminals, general aviation, political violence, professional lines, financial institutions, marine, contingency and treaty reinsurance. The company's operating segments include Specialty Longtail, Specialty Short tail and Reinsurance. The majority of revenue is derived from the Specialty Short-tail segment, which comprises business lines with underwriting risks assumed in the form of property and specialty lines insurance and of short-term nature with respect to related claims.